Skip to main content
Clinical Trials/JPRN-UMIN000015330
JPRN-UMIN000015330
Recruiting
Phase 2

A phase II trial of neoadjuvant chemotherapy using the combination of gemcitabine and cisplatin for patients with initially unresectable locally advanced biliary tract cancer. - A phase II trial of neoadjuvant chemotherapy using the combination of gemcitabine and cisplatin for patients with initially unresectable locally advanced biliary tract cancer.

Adjuvant therapy for BTC Research Group0 sites50 target enrollmentOctober 3, 2014

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Biliary tract cancer (Intrahepatic cholangiocarcinoma, Extrahepatic cholangiocarcinoma, Gallbladder carcinoma)
Sponsor
Adjuvant therapy for BTC Research Group
Enrollment
50
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 3, 2014
End Date
June 30, 2017
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Adjuvant therapy for BTC Research Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Pulmonary fibrosis or interstitial pneumonia 2\. Severe myelosuppression 3\. Pregnant female, possibly pregnant females, females wishing to become pregnant, and females feeding babies. 4\. Serious renal dysfunction 5\. Serious liver dysfunction 6\. Patients with severe allergy 7\. History of breast or lung radiation 8\. Active infection 9\. Patient with uncontrollable pleural effusion and/or severe edema 10\. Active double cancer 11\. Severe complications including uncontrollable diabetes mellitus. 12\. Severe mental disorder 13\. Inadequate physical condition, as diagnosed by primary physician

Outcomes

Primary Outcomes

Not specified

Similar Trials